Lastly, the effectiveness of checkpoint inhibitors in prostate cancer, such as PD-L1, PD1, and CTLA-4 inhibitors, have been very poor despite multiple attempts to exploit these agents in prostate cancer. The gene discussed is CTLA4; the disease is Familial prostate cancer.